{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:17:48Z","timestamp":1791955068607,"version":"4.3.4"},"reference-count":46,"publisher":"Rockefeller University Press","issue":"4","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.rupress.org\/terms\/"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":216,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007625","name":"Cure Alzheimer\u2019s Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["NS 074501"],"award-info":[{"award-number":["NS 074501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG048986"],"award-info":[{"award-number":["U01AG048986"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG055523"],"award-info":[{"award-number":["R01AG055523"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG054223"],"award-info":[{"award-number":["R01AG054223"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG056061"],"award-info":[{"award-number":["R01AG056061"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005937","name":"Chen Foundation","doi-asserted-by":"publisher","award":["R-86U55A"],"award-info":[{"award-number":["R-86U55A"]}],"id":[{"id":"10.13039\/501100005937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,5]]},"abstract":"<jats:p>A potent \u03b3-secretase modulator (GSM) has been developed to circumvent problems associated with \u03b3-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer\u2019s disease (EOFAD). Unlike GSIs, GSMs do not inhibit \u03b3-secretase activity but rather allosterically modulate \u03b3-secretase, reducing the net production of A\u03b242 and to a lesser extent A\u03b240, while concomitantly augmenting production of A\u03b238 and A\u03b237. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a &amp;gt;40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of A\u03b242 in rat brain by 50%.<\/jats:p>","DOI":"10.1084\/jem.20202560","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T15:50:07Z","timestamp":1614700207000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention"],"prefix":"10.1084","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-4792","authenticated-orcid":true,"given":"Kevin D.","family":"Rynearson","sequence":"first","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-6473","authenticated-orcid":true,"given":"Moorthi","family":"Ponnusamy","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Byrd Alzheimer\u2019s Institute, University of South Florida, Morsani College of Medicine, Tampa, FL 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-1574","authenticated-orcid":true,"given":"Olga","family":"Prikhodko","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6716-1982","authenticated-orcid":true,"given":"Yuhuan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5118","authenticated-orcid":true,"given":"Can","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-3225","authenticated-orcid":true,"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-808X","authenticated-orcid":true,"given":"Brenda","family":"Hug","sequence":"additional","affiliation":[{"name":"Veterans Administration San Diego Healthcare System, La Jolla, CA 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-3043","authenticated-orcid":true,"given":"Mariko","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-9727","authenticated-orcid":true,"given":"Ann","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-1941","authenticated-orcid":true,"given":"Brian","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-6566","authenticated-orcid":true,"given":"Jazmin","family":"Florio","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-3377","authenticated-orcid":true,"given":"Michael","family":"Mante","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-0266","authenticated-orcid":true,"given":"Bahar","family":"Salehi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-2168","authenticated-orcid":true,"given":"Carlos","family":"Arias","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-3241","authenticated-orcid":true,"given":"Douglas","family":"Galasko","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-5351","authenticated-orcid":true,"given":"Brian P.","family":"Head","sequence":"additional","affiliation":[{"name":"Veterans Administration San Diego Healthcare System, La Jolla, CA 4"},{"name":"Department of Anesthesiology, University of California, San Diego, La Jolla, CA 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-6241","authenticated-orcid":true,"given":"Graham","family":"Johnson","sequence":"additional","affiliation":[{"name":"NuPharmAdvise, Sanbornton, NH 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-325X","authenticated-orcid":true,"given":"Jiunn H.","family":"Lin","sequence":"additional","affiliation":[{"name":"Biopharm Consulting Partners, Ambler, PA 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-0718","authenticated-orcid":true,"given":"Steven K.","family":"Duddy","sequence":"additional","affiliation":[{"name":"Integrated Nonclinical Development Solutions, Ann Arbor, MI 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-8278","authenticated-orcid":true,"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"},{"name":"Veterans Administration San Diego Healthcare System, La Jolla, CA 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-9548","authenticated-orcid":true,"given":"William C.","family":"Mobley","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6780","authenticated-orcid":true,"given":"Gopal","family":"Thinakaran","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Byrd Alzheimer\u2019s Institute, University of South Florida, Morsani College of Medicine, Tampa, FL 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-1454","authenticated-orcid":true,"given":"Rudolph E.","family":"Tanzi","sequence":"additional","affiliation":[{"name":"Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-9474","authenticated-orcid":true,"given":"Steven L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, CA 1"},{"name":"Veterans Administration San Diego Healthcare System, La Jolla, CA 4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"2023072815090758300_bib1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.1570","article-title":"Pharmacokinetic and Pharmacodynamic Effects of a \u03b3-Secretase Modulator, PF-06648671, on CSF Amyloid-\u03b2 Peptides in Randomized Phase I Studies","volume":"107","author":"Ahn","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"2023072815090758300_bib2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2023072815090758300_bib3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0896-6273(00)80974-5","article-title":"Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins","volume":"19","author":"Borchelt","year":"1997","journal-title":"Neuron."},{"key":"2023072815090758300_bib4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"2023072815090758300_bib5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"key":"2023072815090758300_bib6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","article-title":"A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain","volume":"398","author":"De Strooper","year":"1999","journal-title":"Nature."},{"key":"2023072815090758300_bib7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2023072815090758300_bib8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2023072815090758300_bib9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized Trial of Verubecestat for Prodromal Alzheimer\u2019s Disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2023072815090758300_bib10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch. Neurol."},{"key":"2023072815090758300_bib11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology."},{"key":"2023072815090758300_bib12","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA."},{"key":"2023072815090758300_bib13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science."},{"key":"2023072815090758300_bib14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer\u2019s Disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"2023072815090758300_bib15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)","volume":"13","author":"Iwatsubo","year":"1994","journal-title":"Neuron."},{"key":"2023072815090758300_bib16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2023072815090758300_bib17","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMe1903193","article-title":"Lowering of Amyloid-Beta by \u03b2-Secretase Inhibitors - Some Informative Failures","volume":"380","author":"Knopman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2023072815090758300_bib18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuron.2010.08.018","article-title":"Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer\u2019s disease","volume":"67","author":"Kounnas","year":"2010","journal-title":"Neuron."},{"key":"2023072815090758300_bib19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.trci.2019.06.006","article-title":"NGP 555, a \u03b3-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses","volume":"5","author":"Kounnas","year":"2019","journal-title":"Alzheimers Dement. (N. Y.)."},{"key":"2023072815090758300_bib20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/humu.20336","article-title":"Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40","volume":"27","author":"Kumar-Singh","year":"2006","journal-title":"Hum. Mutat."},{"key":"2023072815090758300_bib21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","article-title":"A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP \u03b2-CTFs, Not A\u03b2","volume":"104","author":"Kwart","year":"2019","journal-title":"Neuron."},{"key":"2023072815090758300_bib22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2014.2482","article-title":"Effect of potent \u03b3-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers","volume":"71","author":"Liu","year":"2014","journal-title":"JAMA Neurol."},{"key":"2023072815090758300_bib23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJM198108273050902","article-title":"Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia","volume":"305","author":"Mabuchi","year":"1981","journal-title":"N. Engl. J. Med"},{"key":"2023072815090758300_bib24","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology."},{"key":"2023072815090758300_bib25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev. Neurol. (Paris)."},{"key":"2023072815090758300_bib26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0027-5107(00)00076-2","article-title":"The bacterial tryptophan reverse mutation assay with Escherichia coli WP2","volume":"455","author":"Mortelmans","year":"2000","journal-title":"Mutat. Res."},{"key":"2023072815090758300_bib27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0027-5107(00)00064-6","article-title":"The Ames Salmonella\/microsome mutagenicity assay","volume":"455","author":"Mortelmans","year":"2000","journal-title":"Mutat. Res."},{"key":"2023072815090758300_bib28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3233\/JAD-190442","article-title":"The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer\u2019s Disease","volume":"73","author":"Prikhodko","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"2023072815090758300_bib29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin. Neurosci"},{"key":"2023072815090758300_bib30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/em.22060","article-title":"In Vivo Pig-a gene mutation assay: Guidance for 3Rs-friendly implementation","volume":"57","author":"Raschke","year":"2016","journal-title":"Environ. Mol. Mutagen"},{"key":"2023072815090758300_bib31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer\u2019s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"2023072815090758300_bib32","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1016\/j.bmcl.2016.07.011","article-title":"Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme","volume":"26","author":"Rynearson","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2023072815090758300_bib33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115734","article-title":"Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators","volume":"28","author":"Rynearson","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"2023072815090758300_bib34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2023072815090758300_bib35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature."},{"key":"2023072815090758300_bib36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.116.232256","article-title":"The \u03b3-Secretase Modulator, BMS-932481, Modulates A\u03b2 Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers","volume":"358","author":"Soares","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2023072815090758300_bib37","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA."},{"key":"2023072815090758300_bib38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer\u2019s disease amyloid hypothesis: a genetic perspective","volume":"120","author":"Tanzi","year":"2005","journal-title":"Cell."},{"key":"2023072815090758300_bib39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1124\/jpet.116.232249","article-title":"Robust Translation of \u03b3-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects","volume":"358","author":"Toyn","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2023072815090758300_bib40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease","volume":"6","author":"Vassar","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"2023072815090758300_bib41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/archneurol.2012.540","article-title":"Potential use of \u03b3-secretase modulators in the treatment of Alzheimer disease","volume":"69","author":"Wagner","year":"2012","journal-title":"Arch. Neurol."},{"key":"2023072815090758300_bib42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1021\/bi401537v","article-title":"Soluble \u03b3-secretase modulators selectively inhibit the production of the 42-amino acid amyloid \u03b2 peptide variant and augment the production of multiple carboxy-truncated amyloid \u03b2 species","volume":"53","author":"Wagner","year":"2014","journal-title":"Biochemistry."},{"key":"2023072815090758300_bib43","author":"Wagner","year":"2016"},{"key":"2023072815090758300_bib44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/jpet.117.240861","article-title":"Pharmacological and Toxicological Properties of the Potent Oral \u03b3-Secretase Modulator BPN-15606","volume":"362","author":"Wagner","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2023072815090758300_bib45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1124\/dmd.32.2.172","article-title":"Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein\/CYP3A-limited bioavailability in the monkey","volume":"32","author":"Ward","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"2023072815090758300_bib46","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.249","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel \u03b3-secretase modulator, E2212, in healthy human subjects","volume":"54","author":"Yu","year":"2014","journal-title":"J. Clin. Pharmacol."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20202560\/1836443\/jem_20202560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20202560\/1836443\/jem_20202560.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T15:10:26Z","timestamp":1690557026000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/218\/4\/e20202560\/211838\/Preclinical-validation-of-a-potent-secretase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,5]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20202560","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"article-number":"e20202560"}}